China, Sept. 17 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Research on the Construction of a Fetal Position Visualization and Left/Right Identifi... Read More
China, Sept. 17 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'OSCC serum biomarker'. The following are the other relevant details related to the tri... Read More
China, Sept. 17 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Phase II, Single-Arm, Single-Center Clinical Trial of Vebreltinib Enteric Capsules i... Read More
China, Sept. 17 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Research on Key Technologies for Intelligent Precision Radiotherapy of Brain and Liver... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with or ... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muval... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy ... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Ve... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pemb... Read More